Altimmune Q1 2025: Assets $77.8M, Liabilities $72.4M
Ticker: ALT · Form: 10-Q · Filed: May 13, 2025 · CIK: 1326190
| Field | Detail |
|---|---|
| Company | Altimmune, Inc. (ALT) |
| Form Type | 10-Q |
| Filed Date | May 13, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: financials, balance-sheet, quarterly-report
TL;DR
Altimmune's Q1 2025: Assets $77.8M, Liabilities $72.4M. Retained earnings negative $10.8M.
AI Summary
Altimmune, Inc. filed its quarterly report for the period ending March 31, 2025. The company reported total assets of $77.8 million and total liabilities of $72.4 million as of March 31, 2025. Retained earnings stood at a deficit of $10.8 million, while additional paid-in capital was $179.7 million.
Why It Matters
This filing provides a snapshot of Altimmune's financial health, showing a significant gap between assets and liabilities, which could impact its ability to fund future operations or research.
Risk Assessment
Risk Level: medium — The company has a substantial deficit in retained earnings, indicating a history of losses, which could pose financial risks.
Key Numbers
- $77.8M — Total Assets (As of March 31, 2025)
- $72.4M — Total Liabilities (As of March 31, 2025)
- -$10.8M — Retained Earnings (As of March 31, 2025, indicating accumulated losses)
- $179.7M — Additional Paid-In Capital (As of March 31, 2025, reflecting equity raised)
Key Players & Entities
- Altimmune, Inc. (company) — Filer of the 10-Q report
- March 31, 2025 (date) — End of the reporting period
- $77.8 million (dollar_amount) — Total assets as of March 31, 2025
- $72.4 million (dollar_amount) — Total liabilities as of March 31, 2025
- $10.8 million (dollar_amount) — Deficit in retained earnings as of March 31, 2025
- $179.7 million (dollar_amount) — Additional paid-in capital as of March 31, 2025
FAQ
What were Altimmune's total assets and liabilities as of March 31, 2025?
As of March 31, 2025, Altimmune reported total assets of $77.8 million and total liabilities of $72.4 million.
What is the status of Altimmune's retained earnings as of the end of Q1 2025?
Altimmune had a deficit in retained earnings of $10.8 million as of March 31, 2025.
How much additional paid-in capital does Altimmune have as of March 31, 2025?
Altimmune's additional paid-in capital was $179.7 million as of March 31, 2025.
What is the filing date of this 10-Q report for Altimmune, Inc.?
This 10-Q report for Altimmune, Inc. was filed on May 13, 2025.
What was the company's former name before October 16, 2007?
Before October 16, 2007, Altimmune, Inc. was formerly known as Pharmathene, Inc.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 13, 2025 regarding Altimmune, Inc. (ALT).